CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$53.39 USD
-2.28 (-4.09%)
Updated Feb 8, 2023 04:00 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 1 - 20 ( 196 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Biotech Coverage: 2023 Anticipated Drug Approvals and Data Releases
Provider: Brookline Capital Markets
Analyst: CANN L
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CTX110 CARBON Study Data at ASH; Supports Our Outlook
Provider: Brookline Capital Markets
Analyst: CANN L
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Biotech Coverage: Upcoming Data Releases, Medical Meetings, by YE 2022
Provider: Brookline Capital Markets
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
COBALT-RCC Study for CTX130 Presented at SITC; Supports Our Outlook
Provider: Brookline Capital Markets
Analyst: CANN L
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Updated CTX110 CARBON Data in ASH Abstract; Supports Our Outlook
Provider: Brookline Capital Markets
Analyst: CANN L
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q22: BLA Rolling Submission Begins This Month
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Reports Q3 2022; Clinical Programs On-track; Strong Cash Position
Provider: Brookline Capital Markets
Analyst: CANN L
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Biotechnology Coverage: Upcoming Data Releases, Medical Meetings, and FDA-filings by YE 2022
Provider: Brookline Capital Markets
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Correction - Biotech Coverage: Upcoming Data Releases, Medical Meetings, FDA-filings by YE 2022
Provider: Brookline Capital Markets
Analyst: CANN L
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
RMAT Designation for CTX130 in Rare Forms of CTCL; Potential Upside to Our Outlook
Provider: Brookline Capital Markets
Analyst: CANN L